Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Grabowska, Joanna" wg kryterium: Autor


Wyświetlanie 1-3 z 3
Tytuł:
Spectacular efficacy of neoadjuvant chemotherapy in a patient with cervical cancer of IB2 grade according to FIGO 2009
Spektakularna skuteczność chemioterapii neoadiuwantowej u pacjentki z rozpoznaniem raka szyjki macicy w stopniu IB2 według FIGO 2009 r.
Autorzy:
Kaźmierczak, Kamila
Nowakowski, Błażej
Kufel-Grabowska, Joanna
Cholewiński, Witold
Powiązania:
https://bibliotekanauki.pl/articles/1035650.pdf
Data publikacji:
2020
Wydawca:
Medical Education
Tematy:
cervical cancer
neoadjuvant chemotherapy
positron emission tomography
Opis:
The presented case report is an example of a spectacular effect of induction systemic treatment in a patient with locally advanced cervical cancer of IB2 grade according to FIGO 2009 (International Federation of Gynecologist and Obstetrician). The effect of induction chemotherapy (three series in paclitaxel/24 h + cisplatin regimen at an interval of three weeks) was the total metabolic response of the primary tumor and nodal lesions found in FDG-PET/CT (18F-fluorodeoxyglucose – positron emission tomography combined with computed tomography) as well as an image of total regression of the tumor in the obtained postoperative histopathological examination.
Przedstawiony opis przypadku jest przykładem spektakularnego efektu zastosowania chemioterapii neoadiuwantowej (NACT, neoadjuvant chemotherapy) u pacjentki z miejscowo zaawansowanym rakiem szyjki macicy w stopniu IB2 według FIGO 2009 r. (International Federation of Gynecologist and Obstetrician). Efektem zastosowanej chemioterapii indukcyjnej (trzech serii w schemacie paklitaksel/24 h + cisplatyna w odstępie 3-tygodniowym) była całkowita odpowiedź metaboliczna guza pierwotnego i zmian węzłowych stwierdzona w badaniu FDG-PET/CT (18F-fluorodeoksyglukoza – pozytonowa tomografia emisyjna połączona z tomografią komputerową), a także obraz całkowitej odpowiedzi patologicznej w otrzymanym pooperacyjnym badaniu histopatologicznym.
Źródło:
OncoReview; 2020, 10, 2; 69-76
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Suspected ovarian cancer in a young patient with a congenital heart defect and a history of cardiac surgery and pacemaker implantation – difficult therapeutic decisions
Autorzy:
Kaźmierczak, Kamila
Stempniewski, Tomasz
Kufel-Grabowska, Joanna
Nowakowski, Błażej
Powiązania:
https://bibliotekanauki.pl/articles/1035815.pdf
Data publikacji:
2018
Wydawca:
Medical Education
Tematy:
Ca 125 marker
congenital heart defect
endometriosis
ovarian cancer
Opis:
After uterine cancer, ovarian cancer is the second most common female reproductive tract malignancy. In Poland, in 2015, there were 3735 new cases and 2738 deaths from ovarian cancer. Over 80% of all cases are diagnosed in women aged over 50, whereas only 6% – before 35 years of age. Most cases are diagnosed, when clinical symptoms have already appeared, and the disease is at least locally advanced. The case presented below describes a very young 28-year-old woman with a tumour in the pelvis, ascites and very high Ca 125 and HE 4 levels. The clinical symptoms as well as laboratory and imaging tests were suggestive of epithelial ovarian cancer that required urgent surgery due to progression of the disease. The surgery posed a significant risk of complications, but owing to the deterioration of the patient’s condition it was considered necessary. The patient was born with a severe, complex heart defect, had undergone two cardiac surgeries, and had a pacemaker (first VVIR, then DDD). She was also intensively treated for iatrogenic HCV infection and hypothyroidism. A multidisciplinary team (a gynecologist, cardiologist and anesthetist) were behind the decision to carry out a major gynecological operation which ended with success. For the past 6 years, the patient has been under constant oncological follow-up and enjoys a good health.
Źródło:
OncoReview; 2018, 8, 2; 38-41
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Ocular side effects of the taxane-based chemotherapy – do only vascular disorders matter?
Autorzy:
Rzeszotarska, Anna
Stodolska-Nowak, Agata
Kufel-Grabowska, Joanna
Nowakowski, Błażej
Kocięcki, Jarosław
Powiązania:
https://bibliotekanauki.pl/articles/1035681.pdf
Data publikacji:
2019
Wydawca:
Medical Education
Tematy:
chemotherapy
ophthalmological complications
taxanes
Opis:
Taxanes, whose mechanism of action is based on blocking the cells’ division of cells, have been commonly used in the chemotherapy process for over two decades. The indications for the use of taxanes include ovarian cancer, breast cancer, lung cancer, prostate cancer, some of gastrointestinal malignant tumors or Kaposi sarcoma. Currently, chemotherapy based on taxanes, as well as every cytostatic medicine, allows to improve survival outcomes in many patients with diagnosed malignancies, although it also involves the occurrence of adverse effects. These adverse events may be life-threatening or at least they can decline the patient’s quality of life. The main aim of this paper is to feature possible ocular side effects during taxane based chemotherapy. Physicians taking care of patients during chemotherapy based on taxanes, as well as on every other cytostatic medicine, should be aware of these probable ocular complications. An early diagnosis of ophthalmic complications caused by chemotherapy makes it possible to avoid long-lasting adverse effects.
Źródło:
OncoReview; 2019, 9, 3; 59-63
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies